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SUMMARY 
SCHEER, ULRICH (1975) The rifamycin derivative AF/OI3 is cytolytic. Mol. Pharma-
cal., 11, 883-888. 
When intact cells (HeLa S-3, mouse 3T3 fibroblasts, hen erythrocytes) are incubated 
with the rifamycin SV derivative AF/OI3, which is widely used as a potent inhibitor of 
mammalian DNA-dependent RNA polymerases, a rapid and extensive disintegration of 
the plasma membrane takes place. This cell disruption results, for example, in hemoly-
sis of the erythrocytes at concentrations above 50 JLg/ml, in the release of cytoplasmic 
components, including ribosomes, and in dramatic ultrastructural changes in the HeLa 
and mouse 3T3 cells. In HeLa cells incubated for 30 min in 100 JLg/ml of the drug, about 
70% of the RNA, 44% of the protein, and 26% of the phospholipids leak out into the 
medium. The permeability of the plasma membrane is markedly increased, even at 
relatively low AF/OI3 concentrations. In the presence of 20 JLg/ml of the drug, for 
example, 70% of the trichloracetic acid-soluble radioactivity and 10% of the trichlora-
cetic acid-precipitable RNA are released from [3H]uridine-Iabeled He La cells. The 
membranolytic action of AF/013 is higher than that of the nonionic surfactant Triton X-
100. This high toxicity indicates that AF/013 cannot be used as a specific inhibitor of 
RNA polymerases in vivo. 
Rifamycin SV and several of its deriva-
tives, the most common one being rifampi-
cin, are important antibiotics in chemo-
therapy (1). They bind to free bacterial 
DNA-dependent RNA polymerases and 
modify these molecules, thus blocking the 
initiation processes before the onset oftran-
scription (2, 3). Several semisynthetic de-
rivatives of rifamycin SV, especially C-3-
substituted molecules with large side 
chains, also inhibit the RNA-dependent 
DNA polymerase ("reverse transcriptase") 
of RNA tumor viruses and various types of 
mammalian RNA polymerases (4, 5). One 
of the most potent inhibitors of eukaryotic 
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RNA polymerases is a rifamycin deriva-
tive with an aliphatic (octyl) side chain in 
position 3 of the naphthoquinone chromo-
phor (trivial name, 3-formylrifamycin SV 
O-n-octyloxime, or AF/OI3). This com-
pound was shown to inactivate different 
mammalian RNA polymerases nonselec-
tively in vitro and primarily to prevent the 
initiation steps of transcription, whereas 
elongation of the nascent chains was not 
affected (e.g., refs. 6 and 7) or was only 
partially (8, 9) impaired. As to its applica-
tion to living cells, however, it is possible 
that AF/013 might interfere with several 
other metabolic processes. For example, it 
has been reported that this drug almost 
totally inhibits the uptake of exogenous 
nucleosides into HeLa cells (10). In the 
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course of experiments with various inhibi-
tors of transcriptional events the present 
author made observations that raise the 
question whether the inhibition of RNA 
synthesis seen in vivo, for example in nor-
mal and leukemic human blood cells (11) 
and in explanted salivary glands of Chi ron-
omus (12), can be explained by the specific 
molecular mechanism that has been hy-
pothesized from enzyme assays in vitro. 
HeLa S-3 cells grown in suspension, 
mouse 3T3 fibroblasts grown in monolay-
ers, and freshly prepared hen erythrocytes 
were used. The rifamycin SV derivative 
AF/013 was a gift of Dr. Marco Crippa 
(Universite de Geneve, Switzerland). Mass 
spectroscopic analysis (Varian 711) con-
firmed the purity of the compound, with a 
molecular weight of 852 (C46H64N2013). 
AF/013 was freshly dissolved before each 
experiment in DMSOl at a concentration 
of 20 mg/ml and was further diluted with 
the appropriate incubation medium. 
HeLa S-3 cells grown in Eagle's basal 
medium supplemented with 10% fetal calf 
serum were washed 5 times at room tem-
perature in medium 1 (1 mM KH2P04 , 10 
mM Na2HP04 , 154 mM NaCI, and 1 mM 
MgCI2, pH 7.2). In some experiments the 
cells had been labeled for 20 hr by adding 2 
ILCi/ml of [3H]uridine (43 Ci/mmole; Radi-
ochemical Centre, Amersham, England) 
to the growth medium. The washed cell 
pellet was suspended in medium 1 at a 
density of about 1 x 106 cells/ml. Some 
aliquots were incubated with 10-100 ILg/ml 
of AF/013; to the others was added the 
same amount of the pure solvent (0.05-
0.5% DMSO, final concentration). Incuba-
tion was carried out for 30 min at 37° under 
continuous gentle shaking. 
The growth medium of an almost con-
fluent monolayer of 3T3 cells was re-
moved, mixed with AF/013 to give a concen-
tration of 100 ILg/ml, and immediately 
added back to the cells. Controls were 
treated identically with the DMSO solvent 
(final concentration, 0.5%) . 
Blood was obtained from a decapitated 
hen and diluted with 0.9% NaCI solution 
containing 2% of the anticoagulate Li-
I The abbreviations used are: DMSO, dimethyl 
sulfoxide; TeA, trichloracetic acid. 
quemin (Hoffman-La Roche AG, Gren-
zach, Federal Republic of Germany). 
Erythrocytes were enriched by centrifuga-
tion at 300 x g for 10 min and resuspension 
in 0.9% NaCI solution to a final density of 
9 x 107 erythrocytes/ml. To 5-ml aliquots 
increasing amounts of AF/013 (0.1-160 
ILg/ml) were added; controls were incu-
bated with similar quantities of DMSO. 
Incubation was performed at room temper-
ature for 10 min. 
[3H]Uridine-Iabeled HeLa S-3 cells and 
hen erythrocytes were incubated under 
the conditions described above with the 
detergent Triton X-lOO at concentrations 
ranging from 10 to 1000 ILg/ml. Mter incu-
bation the HeLa cells were centrifuged at 
2000 x g for 10 min at 25°, the pellets were 
homogenized in ice-cold 5% TCA using a 
motor-driven Potter-Elvehjem homoge-
nizer, and the supernatants were adjusted 
to 5% TCA in the cold. Mter 30 min the 
TCA-precipitated material was sedi-
mented (3000 x g, 15 min, 4°) and washed 
twice with 5% cold TCA. Protein was deter-
mined by the method of Lowry et al. (13) 
and/or by a modified Nessler reaction (14). 
DNA, RNA, and phospholipids were deter-
mined as described (15). 
Labeled HeLa cells were harvested after 
incubation with AF/013 and the solvent 
DMSO, with DMSO alone, or with Triton 
X-lOO by centrifugation at 2000 x g for 10 
min. Aliquots were taken from the super-
natants in order to determine the radioac-
tivity released from the cells. The cell pel-
lets were then washed three times in me-
dium 1 at room temperature and finally 
homogenized in ice-cold 10% TCA. Mter 30 
min at 4°, the solutions were centrifuged 
at 3000 x g for 15 min. TCA-soluble radio-
activity was determined in the superna-
tants. The pellets were resuspended in 
10% TCA and applied to Whatman GF/C 
glass fiber filters. After thorough washing 
with cold 10% TCA the filters were im-
mersed in 2 ml of "NCS" (Nuclear-Chicago 
solubilizer; AmershamlSearle) and incu-
bated overnight at 40°. Toluene-based scin-
tillation fluid was added, and radioactivity 
was determined in a scintillation counter 
(Betaszint 5000; Berthold Friesecke, Wild-
bad, Federal Republic of Germany). Count-
ing efficiency was corrected for quenching. 
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After incubation, the erythrocytes were 
centrifuged for 5 min at 3000 x g. Hemoly-
sis could readily be judged from the color 
that remained in the supernatant as com-
pared to the control. 
Light micrographs of unfixed 3T3 cells 
grown on Falcon dishes were taken with 
an inverted phase contrast microscope 
(Leitz Diavert). He La S-3 cells were photo-
graphed in phase contrast using a Zeiss 
photomicroscope Ill. For electron micros-
copy, the cells were fixed at room tempera-
ture in 2.5% glutaraldehyde buffered to pH 
7.2 with 0.05 M sodium cacodylate contain-
ing 70 mM KCl and 2 mM MgCl2 • Mter 1 hr 
the cells were washed several times in cold 
cacodylate buffer and incubated in 1% 
OS04 (same buffer) for 2 hr in the cold. 
Dehydration was carried out in graded 
ethanol solutions and propylene oxide, and 
the cells were embedded in Epon 812. Ul-
trathin sections were cut on a Reichert 
ultramicrotome OmU3 • Electron micro-
graphs were taken with a Siemens Elmis-
kop 10l. 
The rifamycin derivative AF/013 at a 
concentration higher than 50 p.g/ml (ap-
proximately 60 P.M) causes immediate dis-
ruption of the plasma membrane, as indi-
cated by the complete hemolysis of hen 
erythrocytes. When erythrocytes are incu-
bated at the same cell density with 50 
p.g/ml of Triton X-lOO, no leakage of he mo-
globin occurs. Hemolysis starts at a deter-
gent concentration of about 180-200 p.g/ml 
(approximately 300 P.M). When He La or 
mouse 3T3 cells are treated with 100 p.g/ml 
of AF/013, striking cytopathic effects are 
observed. Under the light microscope the 
cells appear more refractile and the 
plasma membrane is no longer a distinct 
boundary but reveals the formation of nu-
merous large, bleblike evaginations (ar-
rows in Fig. 1b and inset of Fig. 2d). The 
nuclei stand out against the cytoplasmic 
zones with enhanced contrast as compared 
to the controls (compare Fig. la with 1b 
and the inset in Fig. 2b with that in 2d). 
Electron micrographs demonstrate exten-
sive disintegration not only of the plasma 
membrane, which in most cases is totally 
lost, but also of the endoplasmic reticulum 
(Fig. 2c and d). Cytoplasmic organelles, 
like mitochondria, no longer show their 
FIG. 1. Light microscopic appearance (phase contrast) of mouse 3T3 cells growing in Falcon dishes when 
incubated for 30 min in the absence (a) and presence (b) of rifamycin AFIOl3 (lOO WJ/ml) 
The drug-exposed cells have rounded-off surfaces and show numerous spherical evaginations (e.g., at the 
arrows in Fig. Ib) . Note also the enhanced contrast of their nuclei. x 175. 
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typical internal architecture. In addition, 
ribosomes and polyribosomes, which are 
abundant in control cells (Fig. 2a and b), 
cannot be distinguished in the cytoplasm 
of the drug-exposed cells (Fig. 2c and d). 
Characteristically, the nuclear envelope is 
somewhat better preserved, as is also the 
case for the chromatin and the nucleoli. 
The interchromatinic regions, however, ap-
pear to be less electron-dense, indicating 
leakage of nuclear material. The chemical 
determinations (Table 1) are in agreement 
with these observations. The DNA content 
per cell is unaltered, whereas most of the 
acid-precipitable RNA and nearly half the 
protein is lost. The total phospholipid con-
tent is reduced by about 25%. All this re-
leased material can be recovered from the 
supernatant obtained after centrifugation 
of the cells. Low concentrations of AF/013 
cause a pronounced leakage of charged sol-
utes through the plasma membrane, as 
demonstrated for the [3Hluridine-labeled 
nucleosides, nucleotides, and low molec-
ular weight RNA (Fig. 3). At a drug con-
centration of 10 J-Lg/ml 25% of the TCA-
soluble radioactivity is released, but 
almost all the high molecular weight, 
TCA-precipitable RNA is retained within 
TABLE 1 
Gross composition of HeLa 8-3 cells with and without 
treatment with rifamycin AF/013 (lOO pg/ml , 30 min ) 
Control AF/013- Loss 
treated after 
AF/013 
treatment 
pg/cell pg/cell % 
DNA 14.7 14.8 0 
RNA 26.7 8.6 68 .0 
Protein 447.5 253 .3 43.5 
Phospho-
lipids 35.6 26.3 26.1 
the cells. At an AF/013 concentration of 20 
J-Lg/ml 70% of the TCA-soluble material is 
lost from the cells, compared to only 10% of 
the high molecular weight RNA. A repre-
sentative nonionic surfactant, Triton X-
100, causes a similar leakage only at much 
higher concentrations, i.e., 70 and 100 
J-Lg/ml (Fig. 3). 
The rifamycin SV derivative AF/013, 
when added at concentrations necessary 
for significant inhibition of mammalian 
RNA polymerases in vitro (50-100 J-Lg/ml; 
e.g., refs. 8-10), has a strong membrano-
lytic activity and lyses eukaryotic cells. 
Immediately after exposure to the drug 
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FIG. 3. Leakage of radioactivity contained in 
TCA-soluble (- - - ) and TCA-insoluble (--) frac-
tions of [3Hluridine-Iabeled HeLa 8-3 cells after expo-
sure to various concentrations of AF/013 (0, . ) and 
the nonionic detergent Triton X-lOO (6, . ) 
HeLa 8-3 cells were grown for 20 h in the presence 
of 2 JLCi/ml of [3Hluridine, washed several times in 
medium 1, and then incubated in the same buffer at 
a density of about 1 x 106 cells/ml for 30 min in the 
presence of the specific substance. The solvent 
DM80 alone did not affect the permeability of the 
plasma membrane at the concentrations used for the 
AF/013 experiments . 
FIG. 2. Light and electron micrographs of untreated (a, b) and AF/013-treated (c, d ) HeLa 8-3 cells 
Most of the plasma membrane of the cells that have been incubated for 30 min with 100 JLg/ml of AF/013 is 
lost or appears in isolated blebs (inset in Fig. 2d, arrow); the cytoplasmic region is recognized only as an 
aggregate of large membrane vesicles and filaments (Fig. 2c and d; some microfilaments are denoted by the 
arrow in Fig. 2c). In contrast to the controls (Fig. 2a and b), ribosomes and polyribosomes can no longer be 
recognized in the drug-treated cells. Mitochondria appear destroyed. Note the low electron density of the 
interchromatinic regions in the drug-treated cells, indicative of the loss of nuclear material. N, nucleus; C, 
cytoplasm. a . x 40,000. b. x 8400 (inset, x 750). c. x 47,000. d. x 8000 (inset, x 750). 
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the cells are no longer viable, since the 
plasma membrane is destroyed and the 
internal compartmentalization appears to 
be lost. Most of the cellular RNA and half 
the protein are released into the medium. 
It seems reasonable to assume that the 
AF/013 molecule, owing to its hydrophobic 
side chain, strongly interacts with mem-
brane constituents, by phase partitioning 
or by hydrophobic association, thus caus-
ing the destabilization and, finally, the 
breakdown of the membrane. This mem-
branolytic effect might also explain the 
inhibited nucleoside uptake observed in 
the presence of AF/013 and other rifamycin 
derivatives (10), and the blockade of DNA 
replication seen in vivo (11, 16). Moreover, 
it has been clearly demonstrated that 
AF/013 in vitro interacts nonspecifically 
with several proteins other than nucleic 
acid polymerases (17, 18) and also inhibits 
translation in a cell-free system (10). The 
membranolytic effect of AF/013 is even 
stronger than that of the nonionic deter-
gent Triton X-lOO. In order to achieve a 
release of macromolecules from HeLa cells 
or erythrocytes comparable to that ob-
tained with AF/013, about a 4-fold higher 
concentration of the surfactant is neces-
sary, i.e., a concentration that is known to 
transform cultured mammalian cells into 
"ghost mono layers" (see ref. 19). 
From the above results it is concluded 
that the rifamycin derivative AF/013 (and 
probably also other derivatives with hydro-
phobic side chains) is highly toxic to living 
animal cells and therefore cannot be used 
as a specific inhibitor of DNA-dependent 
RNA polymerases in vivo (12). Other com-
pounds of the rifamycin series, including 
the potent inhibitor of prokaryotic RNA 
polymerases, rifampicin, also appear to ex-
ert toxic effects on eukaryotic cells, as has 
been concluded from studies on the sup-
pressed focus formation in chick fibro-
blasts after infection with Rous sarcoma 
virus (20, 21). 
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